Neurocutaneous Syndromes (Phakomatoses)

• Goldman-Cecil Medicine, p. 4049
• Grainger & Allison's Diagnostic Radiology, p. 1985

1. Neurofibromatosis Type 1 (NF-1)

Genetics and Epidemiology

• Most common neurocutaneous syndrome; incidence 1 in 3,000-4,000 births
• Also the most common autosomal dominant condition overall
• Gene: NF1 on chromosome 17q11.2, encoding neurofibromin (a RAS-GAP tumor suppressor)
• 50% of cases represent new (de novo) mutations

Diagnostic Criteria (at least 2 of the following)

CNS Manifestations

• Optic pathway gliomas (OPGs): most common brain lesion; more often affect optic nerves than the chiasm in NF-1. Most are asymptomatic; chiasmatic involvement risks precocious puberty and visual loss.
• Plexiform neurofibromas (pathognomonic when large), peripheral nerve gliomas
• Learning disability, attention deficit disorder, cerebral vasculopathy

Other Organ Involvement

• Pheochromocytoma, renal artery stenosis, macrocephaly, skeletal abnormalities (pseudoarthrosis of tibia)
• Risk of malignant peripheral nerve sheath tumors (MPNSTs)

Imaging

Treatment

• Mirdametinib (MEK inhibitor) - FDA-approved 2025 for plexiform neurofibromas in NF-1 (PMID 40419758)
• Selumetinib (MEK inhibitor) also used for inoperable plexiform neurofibromas
• Annual ophthalmologic exam; blood pressure monitoring; developmental screening
• Grainger & Allison's Diagnostic Radiology, pp. 1985-1987
• Goldman-Cecil Medicine, p. 4050

2. Neurofibromatosis Type 2 (NF-2)

Genetics

• Gene: NF2 on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor
• Autosomal dominant; less common than NF-1

Hallmark Features

• Bilateral vestibular schwannomas (cranial nerve VIII) - pathognomonic; cause progressive bilateral sensorineural deafness
• Multiple meningiomas, ependymomas, astrocytomas
• Plaque-like intracutaneous tumors; cafe-au-lait macules (~40%)
• Posterior subcapsular cataracts (lens opacities in young adults)

Treatment

• Surgical resection of schwannomas (hearing preservation difficult even with early surgery)
• Bevacizumab (anti-VEGF, 5 mg/kg IV every 2 weeks) can improve hearing in some patients
• Goldman-Cecil Medicine, pp. 4051-4052

3. Tuberous Sclerosis Complex (TSC)

Genetics

• Incidence ~1 in 6,000; autosomal dominant; up to 75% are sporadic mutations
• TSC1 gene at 9q34.3 → encodes hamartin
• TSC2 gene at 16p13.3 → encodes tuberin
• Both proteins together inhibit mTOR (mammalian target of rapamycin); mutations cause mTOR upregulation → uncontrolled cell growth, neuronal migration defects, angiogenesis
• TSC2 mutations tend to produce more severe phenotype

Multi-organ Manifestations

Diagnostic Criteria

MRI of Tuberous Sclerosis

Axial T1 MRI showing subependymal nodules ("candle guttering") lining the lateral ventricles in tuberous sclerosis complex.

Treatment

• mTOR inhibitors have dramatically altered prognosis:
  • Everolimus (10 mg/day): reduces angiomyolipoma size in ~40%; reduces SEGA by ≥50% in ~1/3 of patients
  • Everolimus also approved for intractable epilepsy due to TSC
  • Lesions regrow when medication is stopped
  • Topical rapamycin (0.1%) shrinks facial angiofibromas
  • Sirolimus (2 mg/day) approved for LAM
• Vigabatrin is first-line for infantile spasms in TSC
• Surgical resection if seizure focus localized to cortical dysplasia
• Goldman-Cecil Medicine, pp. 4049-4050

4. Sturge-Weber Syndrome (Encephalotrigeminal Angiomatosis)

Genetics

• Sporadic (not familial); incidence ~1 in 20,000
• Caused by a somatic mosaic mutation in GNAQ (chromosome 9q21) - not detectable on blood-based genetic testing

Classic Triad

1. Port-wine stain (capillary hemangioma) of upper face in the distribution of cranial nerve V1 (ophthalmic branch)
2. Ipsilateral leptomeningeal angioma (usually parieto-occipital)
3. Ocular abnormalities: glaucoma, choroidal hemangioma

Classic port-wine stain (capillary hemangioma) affecting the right face and extending beneath the hairline. The lesion thickens and becomes nodular over time.

Neurologic Features

• Focal-onset epilepsy (most common neurologic manifestation)
• Variable cognitive impairment, hemiparesis, hemianopia
• Classic "tramline" (double-contour) cortical calcification on CT (may be absent in infants)
• Only individuals with port-wine stain of the upper face and periorbital area develop leptomeningeal angioma; only ~15% of people with an upper facial nevus have brain involvement

MRI Findings

• Leptomeningeal enhancement (pial angioma) on contrast T1
• Cortical atrophy of the affected hemisphere
• Enlarged ipsilateral choroid plexus

Brain MRI showing left frontal-parietal-occipital leptomeningeal enhancement and cortical atrophy in Sturge-Weber syndrome (postcontrast T1, lower row).

Treatment

• Laser therapy for port-wine stain
• Antiepileptic drugs; surgical excision of epileptogenic cortex if refractory
• Periodic glaucoma screening throughout life (glaucoma can occur even without neurologic involvement)
• Goldman-Cecil Medicine, pp. 4052-4053
• Kanski's Clinical Ophthalmology, p. 2263

5. Von Hippel-Lindau (VHL) Disease

Genetics

• Autosomal dominant; gene: VHL tumor suppressor at chromosome 3p25-26
• VHL protein normally targets HIF (hypoxia-inducible factor) for degradation; loss of VHL leads to HIF overactivation and VEGF overproduction → angiogenesis

Clinical Features (onset typically 3rd-4th decade)

VHL Subtypes

Diagnosis

• More than one brain hemangioblastoma, OR one hemangioblastoma + visceral manifestation, OR one manifestation + positive family history
• Genetic testing detects VHL mutation in essentially all affected individuals

Surveillance & Treatment

• Annual ophthalmologic exam, annual BP monitoring, pheochromocytoma screening every 5 years, abdominal ultrasound from age 16 years
• Surgical resection of brain tumors, RCC, pheochromocytoma; gamma knife for smaller CNS tumors
• Pazopanib (tyrosine kinase inhibitor, 800 mg/day) for progressive lesions
• Goldman-Cecil Medicine, pp. 4053-4054

6. Ataxia-Telangiectasia (Louis-Bar Syndrome)

Genetics

• Autosomal recessive; gene: ATM (ataxia telangiectasia mutated) at 11q22.3
• ATM encodes a serine/threonine kinase activated by DNA double-strand breaks; loss leads to defective DNA repair

Clinical Features

• Progressive cerebellar ataxia (onset in early childhood, Purkinje cell degeneration)
• Oculocutaneous telangiectasias (conjunctivae, ears, nasal mucosa, antecubital/popliteal fossae)
• Recurrent sinopulmonary infections (combined T + B cell immunodeficiency; deficient IgA)
• Oculomotor apraxia
• High risk of malignancies (leukemia, lymphoma, breast cancer in ATM heterozygote females)
• Radiosensitivity (avoid X-ray radiation)
• Elevated serum AFP and CEA; MRI shows cerebellar atrophy
• Quick Compendium of Clinical Pathology, p. 3462
• Bradley and Daroff's Neurology in Clinical Practice

7. Summary Table of Key Neurocutaneous Syndromes

Key Points to Remember

• The phakomatoses share a common ectodermal origin of skin and nervous system - hence both are affected
• NF-1 is diagnosed clinically (cafe-au-lait + neurofibromas + Lisch nodules); MEK inhibitors (mirdametinib/selumetinib) are now first-line for plexiform neurofibromas
• TSC management is transformed by mTOR inhibitors (everolimus, sirolimus)
• Sturge-Weber is caused by a somatic (non-heritable) GNAQ mutation - only 15% of port-wine stains involve the brain
• VHL = think hemangioblastoma + RCC + pheochromocytoma; VEGF pathway is the therapeutic target
• Ataxia-telangiectasia: the only AR member in this group; always screen for malignancy and avoid ionizing radiation

Recent update (2025): Mirdametinib received FDA approval for NF-1-related plexiform neurofibromas (Hoy SM, Drugs 2025; PMID 40419758).

Polymorphic Light Eruption (PMLE)

Epidemiology

• Prevalence 10-20% of the general population in temperate climates
• Prevalence is inversely related to latitude: highest in Scandinavia (~22%), high in the UK and northern US (10-15%), low in Australia (~5%), and rare near the equator (~1% in Singapore) - explained by year-round UV exposure producing sustained immunologic tolerance ("hardening") in sunny climates
• Female predominance (~4:1); onset typically in the 2nd and 3rd decades
• Occurs in all skin types and all racial groups; pinhead papular variant linked to darker Fitzpatrick types (African American, Asian)
• Skin type I carries highest risk; skin type IV the lowest in pan-European studies
• Up to 70% of the population may carry a genetic susceptibility, though not all express clinical disease due to variable penetrance
• Fitzpatrick's Dermatology, p. 1641
• Dermatology 2-Volume Set 5e, p. 1865

Pathogenesis

Normal UV Response (absent in PMLE)

• Depletion of epidermal Langerhans cells
• Neutrophilic infiltration into skin
• Release of immunosuppressive cytokines (IL-4, IL-10) - a Th2 micromilieu
• Net effect: suppression of contact hypersensitivity and induction of hapten-specific tolerance

What Goes Wrong in PMLE

• Langerhans cells persist (CD1a+ cells are not depleted after UV exposure)
• Neutrophil infiltration is impaired - chemotaxis is defective
• Reduced IL-4 and IL-10 production
• Shift to a Th1 cytokine profile rather than the normal Th2 profile
• This creates a permissive environment for hypersensitivity against UV-modified skin molecules
• Elevated baseline levels of IL-1 family pro-inflammatory cytokines are found in PMLE

Photoantigens

Why "Hardening" Works

• Fitzpatrick's Dermatology, pp. 1645-1646
• Dermatology 5e, p. 1865

Clinical Features

Trigger & Timing

• Triggered by UVA, UVB, and rarely visible light - from sunlight, tanning beds, or phototherapy units
• Action spectrum: predominantly UVA (most common), UVB, rarely visible light
• Lesions appear within minutes to hours (up to 2 days) after first significant UV exposure of the season
• Most severe in spring and early summer in temperate climates; tends to improve as summer progresses ("hardening")
• Resolves spontaneously within days to a week without scarring

Lesion Morphology

Clinical Photo - Papular/Plaque Type

PMLE: erythematous papules on the forearm appearing within hours of sun exposure.

Plaque type PMLE: A) Urticarial plaques and papules on the chest/shoulders in a young man. B) Detail. C) Band-like lesions on the sun-exposed neck. D) Thick elevated plaques on the extensor arm, involving the elbow.

Distribution

• Symmetrically distributed on sun-exposed skin: dorsa of hands, forearms, chest, shoulders, V-neck area, lower legs
• Face is sometimes involved but may be relatively spared due to chronic daily UV exposure providing natural hardening
• Sun-protected areas are typically uninvolved

Symptoms

• Pruritus is a consistent feature - often intense
• No systemic symptoms (fever, malaise)

Histopathology

• Epidermal spongiosis (intercellular edema)
• Papillary dermal edema (prominent)
• Superficial and deep perivascular mixed-cell infiltrate (lymphocytes, histiocytes)
• Timed biopsy after solar-simulated irradiation: CD4+ T cells predominate early (within hours), followed by CD8+ T cells in established lesions
• No epidermal necrosis, no interface change (helps distinguish from lupus)
• Fitzpatrick's Dermatology, p. 4376

Clinical Variants

Diagnosis

Clinical (primary approach)

• Characteristic history (spring onset, UV-triggered, resolves spontaneously, recurs annually) + typical morphology is sufficient for diagnosis in most cases
• No specific laboratory test

Investigations in Atypical Cases

• Phototesting: typically normal MED to UVB and UVA (unlike chronic actinic dermatitis); presence of PMLE is not reflected in abnormal MED
• Photoprovocation test: Repeated suberythemal doses of UVA or UVB reproduce PMLE lesions in 60-90% of affected patients; most sensitive to UVA
• Skin biopsy: helpful if diagnosis is uncertain; biopsy provoked lesions for highest yield
• ANA, anti-dsDNA, anti-Ro/La: to exclude lupus erythematosus (most important differential - especially subacute cutaneous LE)

Differential Diagnosis

Course and Prognosis

• Chronic, episodic condition with slow tendency toward improvement over years
• In a 32-year follow-up study: 24% of patients achieved complete resolution, 51% reported symptomatic improvement, 24% had equal or worsening symptoms
• PMLE does not increase risk of skin cancer (though UV-induced immunosuppression in normal skin does)
• "Hardening" during the season naturally reduces severity as summer progresses
• Goldman-Cecil Medicine, p. 4053
• Fitzpatrick's Dermatology, p. 4651

Management

1. Photoprotection (Mild Disease)

• Broad-spectrum sunscreen covering both UVA and UVB (SPF ≥30; high UVA protection is essential - moderate UVA protection is often insufficient)
• SPF 45 with high UVA protection applied at 1 mg/cm² can prevent UV-provoked PMLE in most patients
• Protective clothing, sun avoidance (especially during peak hours)

2. Acute Treatment

• Topical corticosteroids: reduce inflammation and itch; shorten eruption
• Oral antihistamines: adjunct for pruritus relief
• Short course of oral prednisolone (20-30 mg/day tapered over several days): effective for infrequent, severe flares (e.g., vacations); taken at first sign of pruritus

3. Prophylactic Photohardening (Moderate-Severe Disease)

• Narrowband UVB (NB-UVB): 3 sessions/week for 15-20 treatments in early spring; restores Langerhans cell depletion and neutrophil influx
• PUVA (psoralen + UVA): alternative to NB-UVB; similar efficacy
• Mechanism: re-establishes normal UV-induced immunosuppressive milieu in skin

4. Other Agents

• Hydroxychloroquine: evidence from controlled trial; useful in cases not responding to photohardening
• Afamelanotide (alpha-MSH analog): clinical trial evidence for prevention
• Oral antioxidants (nicotinamide, beta-carotene, Polypodium leucotomos extract): modest protective effect as supplements; a 2025 systematic review (PMID 39804624) found evidence for Polypodium leucotomos and other oral photoprotectants
• Biologics/JAK inhibitors: under investigation; a 2026 systematic review (PMID 41192435) evaluated monoclonal antibodies and JAK inhibitors in idiopathic photosensitive disorders - still emerging data

Key Points Summary

Recent evidence: A 2025 immunopathogenesis review (PMID 41655098) highlights the role of effector/regulatory T cell imbalance and cytokine dysregulation (IL-1 family, Th1 predominance) as therapeutic targets - JAK inhibitors and biologics targeting this pathway are now under active investigation.

• Fitzpatrick's Dermatology Vol 1-2, Ch. 92
• Dermatology 2-Volume Set 5e, Ch. 87
• Goldman-Cecil Medicine, p. 4053

Important clarification: "PML" (Progressive Multifocal Leukoencephalopathy) and "PMLE" (Polymorphic Light Eruption) are two entirely different conditions. Your previous questions were about PMLE (a photodermatosis). The JC virus causes PML - a demyelinating brain disease. The similarity in abbreviations can create confusion. This answer covers PML caused by JC virus in full.

PML - Progressive Multifocal Leukoencephalopathy

Definition

• Bradley and Daroff's Neurology in Clinical Practice, p. 1640
• Robbins Pathologic Basis of Disease, p. 1170

The JC Virus

• Named after John Cunningham, the patient from whom it was first isolated
• A small non-enveloped double-stranded DNA polyomavirus (Polyomaviridae family)
• Seroprevalence: 70-90% of adults have antibodies, indicating ubiquitous primary infection in childhood or early adulthood - usually completely asymptomatic
• Less than 10% of healthy individuals show evidence of ongoing viral replication
• JC virus establishes latency in the kidneys, bone marrow, lymphoid tissue, and possibly the brain
• PML is the only known clinical complication of JC virus infection

Epidemiology and Predisposing Conditions

Pathogenesis

1. Primary infection in childhood: asymptomatic; virus establishes latency in kidneys, bone marrow, lymphoid tissues
2. Reactivation under immunosuppression: impaired JCV-specific CD4+ and CD8+ T cell surveillance allows viral replication
3. Hematogenous spread to the CNS (mechanism debated - may involve infected B cells crossing the blood-brain barrier; natalizumab blocks lymphocyte trafficking via α4-integrin, possibly trapping JCV-infected cells in the CNS)
4. Oligodendrocyte infection: JCV enters oligodendrocytes (and to a lesser extent astrocytes and cerebellar granule cells); viral replication causes lytic cell death
5. Demyelination: loss of oligodendrocytes strips axons of myelin, producing expanding foci of demyelination

Clinical Features

• Onset: subacute to gradual; relentlessly progressive over weeks to months
• Symptoms depend on lesion location - predominantly subcortical white matter (parieto-occipital most common):

• No fever (distinguishes from bacterial/fungal infections)
• In HIV/AIDS PML: typically presents as a late AIDS complication
• In natalizumab PML: may present in a patient with otherwise normal immune status; often more inflammatory ("inflammatory PML")

Pathology

Gross

• Irregular, ill-defined white matter lesions ranging from millimeters to large confluent regions
• Predominantly subcortical distribution; spares the cortical ribbon ("scalloping out" of the grey-white border)
• Parieto-occipital lobes most commonly affected; cerebellum and brainstem also involved; spinal cord very rarely

Histology (Robbins classic triad)

PML histology: note the enlarged, hyperchromatic oligodendrocyte nuclei containing glassy amphophilic viral inclusions, bizarre giant astrocytes with irregular hyperchromatic nuclei, lipid-laden macrophages, and demyelination.

1. Altered oligodendrocytes - greatly enlarged nuclei with glassy amphophilic intranuclear viral inclusions (found at lesion edge)
2. Bizarre giant astrocytes - one to several irregular, hyperchromatic nuclei; mitotically active appearance
3. Demyelination - lipid-laden macrophages in center of lesions; reduced axons

• Robbins Pathologic Basis of Disease, p. 1170

Neuroimaging

MRI (modality of choice)

PML MRI: A) T2 - widespread hyperintense signal in left corona radiata with subcortical involvement. B) DWI. C) Characteristic peripheral hyperintense DWI rim at the advancing front of active demyelination (a hallmark of PML).

• Grainger & Allison's Diagnostic Radiology, p. 1480
• Key pattern: Subcortical lesion that "scallops out" the grey-white border, sparing the cortex; no mass effect in classical PML

Diagnosis

CSF Analysis

• Usually normal or nonspecific (mild pleocytosis, mildly elevated protein)
• JC virus DNA PCR in CSF: highly specific; sensitivity ~70-90%. When positive in the correct clinical and MRI context, brain biopsy is not required.
• Negative CSF PCR does not exclude PML (especially post-treatment or inflammatory PML)

Brain Biopsy

• Required when CSF PCR is negative but clinical/imaging suspicion remains high
• Shows the histologic triad above; JCV immunohistochemistry or in situ hybridization confirms diagnosis

Natalizumab risk stratification - JCV antibody index

• Antibody index <0.4: considered negative (very low risk)
• 0.4-0.9: low risk
• 0.9-1.5: medium risk
• >1.5: high risk - consider drug switch
• Prior natalizumab exposure duration and prior immunosuppressant use multiply the risk

Treatment and Management

1. Restore Immune Competence (cornerstone)

• Immediate initiation or optimization of ART (combination antiretroviral therapy) is the most effective intervention
• ART restores CD4+ T cell count and JCV-specific T cell responses
• 1-year survival with ART: ~50% (pre-ART era: mean survival 2-4 months)
• Better outcomes with: CD4 >300/μL, low/undetectable HIV viral load, undetectable JCV in CSF after ART, contrast-enhancing lesions at diagnosis

• Immediately discontinue natalizumab
• Accelerate drug elimination with plasma exchange (PLEX) - 5 sessions - to rapidly remove natalizumab and restore CNS immune surveillance
• Monitor closely for IRIS after drug removal

2. No Proven Specific Antiviral Therapy

• Cytarabine (cytosine arabinoside) - intravenous and intrathecal - failed RCT in HIV-PML
• Cidofovir - failed RCT in HIV-PML
• Mefloquine - prospective multicenter trial showed no benefit
• Mirtazapine (5-HT2A receptor antagonist, inhibits JCV binding to oligodendrocyte serotonin receptors) - case reports only; no RCT evidence
• Interferon-alpha - retrospective non-controlled data only

3. Immunotherapy (Emerging)

• Pembrolizumab (PD-1 inhibitor): small case series showed clinical improvement and stabilization by restoring anti-JCV T cell responses - promising but unvalidated
• JCV-specific cytotoxic T lymphocyte (CTL) infusions: positive results in small case series; currently experimental
• Both approaches target the fundamental problem: restoring JCV-specific cellular immunity

4. Managing IRIS (Immune Reconstitution Inflammatory Syndrome)

• PML-IRIS: new or worsening CNS inflammation despite viral suppression
• Imaging: new contrast enhancement, increased FLAIR signal, mass effect, restricted diffusion - on a background of previously non-enhancing lesions
• CSF: pleocytosis
• Treatment: IV glucocorticoids (no controlled trial evidence; used empirically)
• PML-IRIS is actually associated with better long-term outcome than non-inflammatory PML - it reflects immune recovery

Prognosis

• Up to 80% of survivors have significant neurologic sequelae
• Up to 50% of long-term HIV/AIDS survivors (>24 months) experience meaningful recovery
• Favorable prognostic factors: higher CD4, low viral load, undetectable CSF JCV after treatment, presence of contrast enhancement (reflects intact immune response)

Summary

Recent evidence: A 2023 Neurology review (PMID 37487750) emphasizes that restoring JCV-specific cellular immunity is the critical determinant of viral clearance and survival, and calls for validated biomarkers and definitive clinical trials. A 2025 review on natalizumab-PML (PMID 40621097) outlines the current JCV antibody index-based risk stratification as the standard of care for risk mitigation in natalizumab-treated patients.

Pericardial Effusion

Definition and Normal Physiology

• Grainger & Allison's Diagnostic Radiology, p. 359
• Textbook of Clinical Echocardiography, p. 306

Etiology

Key point: Bacterial/fungal infection, HIV, and malignancy carry higher risk of progressing to tamponade.

• Mulholland & Greenfield's Surgery, p. 4572
• Textbook of Clinical Echocardiography, Table 10.1

Pathophysiology

1. Volume of fluid
2. Rate of accumulation

Pressure-Volume Relationship

Cardiac Tamponade Physiology

• Tamponade occurs when pericardial pressure exceeds intracardiac chamber pressure, impairing filling
• Low-pressure thin-walled chambers (atria) are compressed before ventricles
• Right heart is affected first → underfilling of left heart → reduced cardiac output
• Tamponade generally occurs when filling pressures reach 15-20 mm Hg
• Can occur at lower pressures in hypovolemia (dialysis, diuretics, hemorrhage)
• The body compensates via adrenergic response (tachycardia, increased contractility) - beta-blockers impair this compensation
• Textbook of Clinical Echocardiography, p. 307
• Mulholland & Greenfield's Surgery, p. 4572

Clinical Features

Uncomplicated Pericardial Effusion

• Often asymptomatic, discovered incidentally on imaging
• Symptoms when present: dyspnea (especially positional), chest heaviness, cough (from bronchial compression), dysphagia
• Large chronic effusions may be well-tolerated with few symptoms

Cardiac Tamponade - Clinical Signs

1. Hypotension (reduced cardiac output)
2. Jugular venous distension (JVD) - elevated venous pressure
3. Muffled heart sounds

• Tachycardia - sensitivity 100% for tamponade
• JVD - sensitivity 100% for tamponade
• Pulsus paradoxus >10 mmHg fall in systolic BP during inspiration
  • Sensitivity 98%, specificity 83%; LR+ 5.9, LR- 0.03
  • Mechanism: inspiratory RV expansion compresses LV in a fixed pericardial space, reducing LV stroke volume
  • Absent in: LV dysfunction, ASD, positive-pressure ventilation, aortic regurgitation, regional tamponade
• Loss of y-descent on JVP waveform (tricuspid cannot open freely; blood only enters when blood leaves)
• Diaphoresis, anxiety

Differentials to consider: right heart failure, pulmonary embolism (overlapping presentations).

• Symptom to Diagnosis Guide, p. 5180
• Mulholland & Greenfield's Surgery, p. 4573

Investigations

1. ECG

• Sinus tachycardia - most common finding
• Low voltage - attenuation of complexes by surrounding fluid
• Diffuse ST elevation and PR depression (if associated pericarditis)
• Electrical alternans - pathognomonic for large effusion/tamponade; alternating QRS axis/amplitude due to the heart swinging back and forth within the effusion

ECG showing electrical alternans - alternating QRS morphology every other beat - a hallmark of large pericardial effusion with tamponade physiology.

2. Chest X-Ray

• Normal when <200 mL of fluid
• "Water-bottle" or flask-shaped cardiac silhouette when ≥200 mL
• Symmetric enlargement with acute cardiophrenic angles
• Hilar vessels obscured (unlike simple cardiomegaly where hila are conspicuous)
• Posterior pericardial fat pad sign on lateral view: fat stripe displaced posteriorly
• Curvilinear lucency along the left cardiac border (pericardial fat line)
• Rapid change in heart size with no change in pulmonary vascular pattern (fluid accumulates faster than pulmonary congestion can develop)

3. Echocardiography (primary imaging investigation)

• Echo-lucent (anechoic) space around the heart
• Small effusion: seen only posterior to LV free wall in systole
• Moderate-large effusion: circumferential, surrounds the heart
• Distribution is gravity-dependent (posterolateral LV wall, inferior to RV, superior pericardial recess)
• Important pitfall: Anterior epicardial fat can mimic a small effusion (fine speckled pattern rather than truly anechoic)

• Right atrial systolic collapse - earliest sign; sensitivity ~100%
• Right ventricular diastolic collapse - more specific; >1/3 diastole = significant
• IVC plethora - dilated IVC (<50% collapse with sniff)
• Exaggerated respiratory variation (Doppler): >25% decrease in mitral inflow velocity with inspiration (vs normal <10%); reciprocal increase in tricuspid inflow
• Ventricular interdependence: RV enlarges on inspiration while LV shrinks (septal bounce)

Apical 4-chamber echocardiogram showing large pericardial effusion (PE) with diastolic right atrial collapse (arrow). LV=left ventricle, RV=right ventricle, LA=left atrium, RA=right atrium.

4. CT

• More accurate than echo for loculated effusions (especially anterior)
• Quantifies volume more precisely (trace the effusion on serial slices)
• Characterizes effusion: simple/transudative (near water density, -10 to +10 HU) vs complex/exudative/hemorrhagic (higher HU)
• Detects pericardial thickening, enhancement, calcification (best modality for calcification)
• Identifies associated mediastinal or pulmonary pathology

5. MRI

• Best for tissue characterization:
  • Transudative/exudative (no debris): T1 hypointense, T2/FLAIR/SSFP hyperintense
  • Proteinaceous or hemorrhagic: T1 hyperintense
  • Fibrinous strands visible on GRE/SSFP
• Late gadolinium enhancement of pericardium = active inflammation
• Can identify associated pericardial thickening and assess for constriction

Cardiac MRI - pericarditis with effusion. A) T1: no signal in effusion, mild pericardial thickening. B) SSFP cine: bright hyperintense effusion. Pericardial enhancement suggests active inflammation.

6. Pericardial Fluid Analysis

Management

Step 1: Assess hemodynamic stability

• Hemodynamically unstable (hypotension + JVD + tachycardia + pulsus paradoxus) → emergency pericardiocentesis
• IV fluids and inotropes can temporize hypotension but must not delay drainage

Step 2: Drainage - Pericardiocentesis

• Cardiac tamponade (emergent)
• Large symptomatic effusion (>20 mm on echo)
• Suspected purulent or tuberculous pericarditis
• Diagnostic (unexplained effusion, suspect malignancy)
• Persistent moderate-large effusion not responding to medical therapy

• Echocardiography-guided (standard of care; reduces complications)
• Subxiphoid approach (most common) or apical
• Indwelling catheter for 2-3 days allows complete drainage and reduces recurrence
• Fluid should be sent for cytology, culture, ADA, protein, LDH, glucose

• Loculated or posterior effusions (may need surgical drainage)
• Coagulopathy (correct first if possible)
• Aortic dissection (drainage will accelerate death - needs surgery)

• Loculated effusion
• Blood clots (e.g., post-cardiac surgery)
• Bacterial/tuberculous pericarditis (thick exudate may block needle)
• Recurrent malignant effusion (consider pericardiectomy/pericardial window)

Step 3: Treat the underlying cause

Malignant Pericardial Effusion (special consideration)

• Fluid cytology positive in ~85% of cases
• Complete drainage with indwelling catheter 2-3 days is treatment of choice
• Colchicine 0.6 mg twice daily after drainage reduces recurrence
• Pericardial window (surgical or percutaneous balloon) for recurrent effusions
• Goldman-Cecil Medicine; Mulholland & Greenfield's Surgery, pp. 4572-4575

Cardiac Tamponade - Summary

Complication: Constrictive Pericarditis

• Kussmaul's sign (paradoxical JVP rise on inspiration)
• Pericardial knock (loud S3 = abrupt cessation of diastolic filling)
• Ascites, hepatomegaly, peripheral edema (right heart failure picture)
• Treatment: pericardiectomy

Quick Reference Classification

2025 ACC Guidance (PMID 40767817): The 2025 ACC Expert Consensus Statement on Pericarditis/Pericardial Disease now emphasizes multimodality imaging (echo, CT, CMR), risk stratification for high-risk features (fever >38°C, subacute onset, large effusion, troponin rise, immunosuppression), and the role of colchicine as standard adjunctive therapy. A 2023 review on chronic pericardial effusion (PMID 36773704) highlights that idiopathic cause remains most common chronically, with colchicine and pericardiectomy as the main strategies for refractory cases.